top of page
![Diagram of an NAD molecule](https://static.wixstatic.com/media/7fb8ed_668501cb4d83451fb58102b7ddd84eaf~mv2.jpg/v1/fill/w_170,h_170,al_c,q_80,usm_0.66_1.00_0.01,enc_avif,quality_auto/NAD%20Molecule%20300%20-%20rotated.jpg)
Science of NAD
How are your NAD levels today?
![Diagram of an Nicotinamide Riboside molecule](https://static.wixstatic.com/media/7fb8ed_2330d424e8b943c0a0efb437a9600a53~mv2.jpg/v1/fill/w_83,h_124,al_c,q_80,usm_0.66_1.00_0.01,enc_avif,quality_auto/Nicotinamide%20Riboside%20Molecule.jpg)
![Diagram of a Nicotinamide Riboside Molecule](https://static.wixstatic.com/media/7fb8ed_2330d424e8b943c0a0efb437a9600a53~mv2.jpg/v1/fill/w_83,h_124,al_c,q_80,usm_0.66_1.00_0.01,enc_avif,quality_auto/Nicotinamide%20Riboside%20Molecule.jpg)
Nicotinamide riboside improves MI-induced acute kidney injury through increasing nicotinamide phosphorybosil transferase and NAD renal levels
Journal of Molecular and Cellular Cardiology
December 31, 2022
Habeichi, Nada
Summary
Strong evidence has demonstrated a link between acute myocardial infarction (MI) and acute kidney injury (AKI). A decrease in cardiac and renal nicotinamide adenine dinucleotide (NAD) has been reported post-cardiac and kidney diseases. The correlation between myocardial and kidney NAD homeostasis in the context of MI-induced AKI (Type-1 CRS) and the potential beneficial impact of NAD boosting therapies in this relatively unexplored disease model are yet to be determined.
bottom of page